Peru-15, an improved live attenuated oral vaccine candidate for vibrio cholerae O1

Journal of Infectious Diseases

Volumn 172, Issue 4, 1995, Pages 1126-1129

  Kenner, Julie R ^a,b,c,d   Coster, Trinka S ^a,b,c,d   Taylor, David N ^a,b,c,d   Trofa, Andrew F ^a,b,c,d   Barrera Oro, Maria ^a,b,c,d   Hyman, Tracy ^a,b,c,d   Adams, Jennifer M ^a,b,c,d   Beattie, David T ^a,b,c,d   Killeen, Kevin P ^a,b,c,d   Spriggs, Dale R ^a,b,c,d   Mekalanos, John J ^a,b,c,d   Sadoff, Jerald C ^a,b,c,d  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c Virus Research Institute ^*  (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHOLERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; GENE DELETION; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECA GENE; VACCINATION; VIBRIO CHOLERAE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHOLERA; CHOLERA VACCINES; DIARRHEA; HUMANS; SAFETY; TREATMENT OUTCOME; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 0029119424     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/172.4.1126     Document Type: Article

References (14)

1. Sack DA, Cholera control. Lancet 1994;344:616-7
2. Tauxe R, Seminario L, Tapia R, et al. The Latin American epidemic. In: Wachsmuth IK, Blake PA, Olsvik O, eds. Vibrio cholerae and cholera: molecular to global perspectives. Washington, DC: American Society for Microbiology, 1994:321-44
3. Levine MM, Black RE, Clements ML, et al. Duration of infection-derived immunity to cholera. J Infect Dis 1981; 143:818-20
4. Glass RI, Claeson M, Blake PA, et al. Cholera in Africa: lessons on transmission and control for Latin America. Lancet 1991;338:791-5
5. Mekalanos JJ, Sadoff JC. Cholera vaccines: fighting an ancient scourge. Science 1994;265:1387-9
6. Clements JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990; 1: 270-3
7. Levine MM, Kaper JB, Herrington D, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccine CVD 103 and CVD 103-HgR. Lancet 1988;2:467-70
8. Taylor DN, Killeen KP, Hack DC, et al. Development of a live, oral, attenuated vaccine against El Tor cholera. J Infect Dis 1994; 170:1518-23
9. Coster TS, Killeen KP, Waldor MK, et al. Safety, immunogenicity, and efficacy of a live, attenuated Vibrio cholerae 0139 vaccine prototype, Bengal-15. Lancet 1995;345:949-52
10. Tacket CO, Losonsky G, Nataro JP, et al. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a A ctxA Azot A ace derivative of El Tor Ogawa Vibrio cholerae. J Infect Dis 1993;168:1536-40
11. Levine MM, Tacket CO. Recombinant live cholera vaccines. In: Wachs muth IK, Blake PA, Olsvik O, eds. Vibrio cholerae and cholera: molecular to global perspectives. Washington, DC: American Society for Microbiology, 1994:395-413
12. Levine MM, Kaper JB, Herrington D, et al. Volunteer studies of deletion mutants of Vibrio cholerae Ol prepared by recombinant techniques. Infect Immun 1988;56:161-7
13. Ramamurthy T, Garg S, Sharma R, et al. Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet 1993;341:703-4
14. Albert MJ, Siddique AK, Islam MS, et al. Large outbreak of clinical cholera due to Vibrio cholerae non-Ol in Bangladesh. Lancet 1993; 341:704